Do you want to read an article? Please log in or register.
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Heart FailureHypertension
RECOMMENDED
Related content
RECOMMENDED
Heart Failure
Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD
doi: 10.1161/CIRCULATIONAHA.119.044491.
Heart Failure
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
Swiss Med Wkly.
Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M
doi: 10.4414/smw.2017.14533.
Heart Failure
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial
Eur J Heart Fail.
Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees
doi: 10.1002/ejhf.1301.
Heart FailureHypertension
Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction
J Am Coll Cardiol.
Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, Olson TP, Borlaug BA
doi: 10.1016/j.jacc.2017.05.029.
Heart Failure
Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry
ESC Heart Fail.
Kapłon-Cieślicka A, Laroche C, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Maggioni AP, Hage C, Lara-Padrón A, Fucili A, Drożdż J, Seferovic P, Rosano GMC, Mebazaa A, McDonagh T, Lainscak M, Ruschitzka F, Lund LH, Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators
doi: 10.1002/ehf2.12817.
Heart, Artery and Coronary DiseasesHeart Failure
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Eur J Heart Fail.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP; TIME-CHF Investigators
doi: 10.1002/ejhf.798.
Atrial FibrillationHeart FailureHypertension
Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
Eur J Heart Fail.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G
doi: 10.1002/ejhf.813.
Heart Failure
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF)
JACC Heart Fail.
Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O'Brien EC
doi: 10.1016/j.jchf.2016.12.018.
Heart Failure
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
JAMA.
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators.
doi: 10.1001/jama.2019.12843.